<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068844</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2019-0617</org_study_id>
    <nct_id>NCT04068844</nct_id>
  </id_info>
  <brief_title>Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas-Arlington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global objective of this study is to determine the mechanisms of exercise intolerance and
      dyspnea on exertion (DOE) in patients with HFpEF and based on this pathophysiology, test
      whether specific exercise training programs (whole body vs single leg) will result in
      improved exercise tolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, non-blinded prospective intervention testing the effects of two
      types of exercise training, whole body and isolated single leg, on HFpEF patients with either
      central or peripheral limitations to exercise training. Subjects will undergo baseline
      maximal exercise testing and invasive right heart catheterization to define exercise
      tolerance and pulmonary and cardiac pressures during exercise. Based on the results of
      baseline testing, subjects will be divided into either centrally limited, defined as
      excessive rise in pulmonary capillary wedge pressure more than 25 mmHg that decreases after
      administration of sub-lingual nitroglycerin resulting in improved exercise tolerance, or
      peripherally limited, defined as no improvement in exercise tolerance despite reduction in
      pulmonary capillary wedge pressure after sublingual nitroglycerin. After baseline testing,
      subjects will be randomized to either whole body cycle exercise supplemented with sublingual
      nitroglycerin to improve training responsiveness or isolated single leg exercise training for
      4 months. After 4 months, subjects will repeat maximal exercise testing and invasive right
      heart catheterization to assess responses to 4 months of exercise training.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>HFpEF patients with either central or peripheral limitations to exercise will be randomly assigned to either whole body or isolated single leg exercise.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aerobic fitness</measure>
    <time_frame>4 months</time_frame>
    <description>Change in peak VO2 after exercise training</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary hemodynamics</measure>
    <time_frame>4 months</time_frame>
    <description>Change in exercise pulmonary capillary wedge pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sympathetic activity</measure>
    <time_frame>4 months</time_frame>
    <description>Change in muscle sympathetic activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg blood flow</measure>
    <time_frame>4 months</time_frame>
    <description>Change in leg blood flow assessed by Doppler velocities in femoral artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac fibrosis</measure>
    <time_frame>4 months</time_frame>
    <description>Change in T1 mapping times by cardiac MRI</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>Central HFpEF whole body exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to whole body cycle training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central HFpEF isolated single leg exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFpEF patients who have a central limitation as the cause of the exercise intolerance randomized to isolated single leg training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral HFpEF whole body exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to whole body cycle training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral HFpEF isolated single leg exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFpEF patients who have a peripheral limitation as the cause of the exercise intolerance randomized to isolated single leg training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise training</intervention_name>
    <description>Exercise training, either whole body or isolated single leg</description>
    <arm_group_label>Central HFpEF isolated single leg exercise</arm_group_label>
    <arm_group_label>Central HFpEF whole body exercise</arm_group_label>
    <arm_group_label>Peripheral HFpEF isolated single leg exercise</arm_group_label>
    <arm_group_label>Peripheral HFpEF whole body exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signs and symptoms of heart failure

          -  an ejection fraction &gt; 0.50

          -  objective evidence of diastolic dysfunction

        Exclusion Criteria:

          -  age &lt; 60 years

          -  BMI &gt; 50 kg/m2

          -  PDE5 inhibitor use

          -  Severe valvular disease

          -  Severe COPD

          -  CKD 4 or higher

          -  Contra-indication to MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Institute for Exercise and Environmental Medicine</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary B Childers</last_name>
      <phone>214-345-6459</phone>
      <email>MaryBChilders@texashealth.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin D Levine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise</keyword>
  <keyword>Hemodynamics,</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

